Retirement Planning Company of New England’s VanEck Biotech ETF BBH Stock Holding History

Retirement Planning Company of New England’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-149	Closed	-$28K	–	274
2021 Q4	$28K	Buy	+149	New	+$28.7K	0.01%	485

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

Retirement Planning Company of New England's BBH Position: Q1 2022 in Review

Retirement Planning Company of New England sold out of VanEck Biotech ETF (BBH) in Q1 2022, closing a stake of 149 shares — an estimated $28K sold.

Retirement Planning Company of New England first reported a position in BBH in Q4 2021 and held it in 1 quarter. The position peaked at $28K in Q4 2021. 115 funds tracked by Wall St. Rank hold BBH as of Q1 2022.

Retirement Planning Company of New England reported no remaining VanEck Biotech ETF position as of Q1 2022 after selling out during the quarter.
Retirement Planning Company of New England sold 149 VanEck Biotech ETF shares in Q1 2022, an estimated $28K.
Retirement Planning Company of New England first reported a position in VanEck Biotech ETF in Q4 2021 and held it in 1 quarter.
Retirement Planning Company of New England's VanEck Biotech ETF position peaked at $28K in Q4 2021.
115 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2022.

Based on Retirement Planning Company of New England's 13F filing for Q1 2022, filed 6 May 2022.